Document:

​

Exhibit 10.1
​
STOCK CONTRIBUTION AGREEMENT
THIS STOCK CONTRIBUTION AGREEMENT (this “Agreement”) is made and entered into as of May 11, 2022 (the “Effective Date”), by and between Avenue Therapeutics, Inc., a Delaware corporation (“Acquirer”) and Fortress Biotech, Inc., a Delaware corporation (“Contributor”).
RECITALS
A.Contributor is the owner and shareholder of record of 250,000 shares of Class A Preferred Stock, par value $0.0001 per share (the “Class A Shares”) and 8,617,653 shares of Common Stock, par value $0.0001 per share (such shares, together with the Class A Shares, the “Shares”), in each case, of Baergic Bio, Inc., a Delaware company (the “Target” and f/k/a Genexion Oncology, Inc.), representing 60.96% of the fully diluted capitalization of the Target.
B.Contributor desires to contribute to the capital of Acquirer, and Acquirer desires to acquire from Contributor, the Shares and Contributor’s rights under the Assumed Contracts (as defined below), subject to the terms and conditions set forth in this Agreement (the “Contribution”).
C.The respective boards of directors of Acquirer and Contributor have determined that the Contribution and the other transactions contemplated by this Agreement (the “Transactions”) are advisable and in the best interest of the stockholders of their respective companies, and accordingly have approved and declared advisable this Agreement and all of the Transactions.
AGREEMENT
In consideration of the foregoing and of the mutual promises and covenants set forth below, the parties agree as follows:
1.Definitions. For purposes of this Agreement, the following capitalized words have the following meanings:
“Acquirer Class A Preferred Shares” means the shares of Class A Preferred Stock of Acquirer with a par value of $0.0001 per share.
“Acquirer Common Shares” means the shares of Acquirer Common Stock.
“Acquirer Common Stock” means the common stock of Acquirer with a par value of $0.0001 per share.
“Acquirer Founders Agreement” means that certain Amended and Restated Founders Agreement, dated September 13, 2016, by and between Contributor and Acquirer.
“Acquirer’s Knowledge” means the actual knowledge of any of David Jin, of the relevant subject matter, after reasonable due inquiry.
​

​

​

“Acquirer Material Adverse Effect” means any event, occurrence, fact, condition or change that (a) has had, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on (a) the business, results of operations, financial condition or assets of Acquirer, or (b) the ability of Acquirer to consummate the Transactions; provided, however, “Acquirer Material Adverse Effect” shall not include, either alone or in combination, any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions or conditions generally affecting the capital, credit or financial markets; (ii) conditions generally affecting the industries or markets in which Acquirer operates; (iii) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (iv) acts of God, including any earthquakes, hurricanes, tornadoes, floods, tsunami, pandemic (including COVID-19) or other natural disasters; (v) any action required or permitted by this Agreement, or any action taken (or not taken) with the written consent of or at the request of Contributor; (vi) any changes in Applicable Laws or accounting rules or principles, including GAAP, or any interpretations thereof; or (vii) the announcement or execution of this Agreement, pendency or completion of the Transactions; provided, however, that any effect resulting from a matter described in any of the foregoing clauses (i) through (iv) or (vi) may be taken into account in determining whether an Acquirer Material Adverse Effect has occurred or is reasonably likely to occur to the extent such effect has a disproportionate adverse effect on Acquirer, taken as a whole, relative to other entities operating in the industries in which Acquirer operates.
“Acquirer Parties” means Acquirer and Acquirer’s Affiliates, and their respective subsidiaries (but excluding Contributor and the Contributor Parties) and the equity holders, directors, officers, employees, contractors, agents and representatives of Acquirer and Acquirer’s Affiliates.
“Acquirer Preferred Shares” means the shares of Acquirer Preferred Stock.
“Acquirer Preferred Stock” means the preferred stock of Acquirer with a par value of $0.0001 per share.
“Action” means any complaint, litigation, claim, audit, assessment, action, suit, arbitration, inquiry, proceeding or investigation by or before any Governmental Authority of any nature, civil, criminal, regulatory or otherwise, in Applicable Law or in equity.
“Affiliate” means any Person which controls, is controlled by, or is under common control with, another Person. A Person is deemed to “control” another Person if it: (i) possesses, directly or indirectly, the power to direct or cause the direction of management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise; or (ii) owns directly or indirectly at least fifty percent of the shares entitled to vote at a general election of directors of such other Person. Notwithstanding the foregoing, for purposes of this Agreement, the Parties acknowledge and agree that: Acquirer’s Affiliates do not include Contributor and its other subsidiaries, and Contributor’s Affiliates do not include Acquirer.
“Applicable Law” means Laws that apply to this Agreement, the Transactions, the Collective Transaction, Contributor, Acquirer, the Target or the Shares.
​

2
​

​

“Assignment and Assumption Agreement” means an Assignment and Assumption Agreement between Contributor and Acquirer to be entered into at the Closing, substantially in the form attached as Exhibit A.
“Assumed Contracts” means the Founders Agreement and the Management Services Agreement.
“Baergic License Agreements” means the Exclusive License Agreement, dated December 17, 2019, by and between the Target and Children’s Hospital Medical Center, d/b/a Cincinnati Children’s Hospital Medical Center and the License Agreement, dated December 17, 2019, by and between the Target and AstraZeneca AB.
“Business Day” means a day other than Saturday or Sunday or any other day on which banks located in New York, New York are required or authorized to be closed.
“Collective Transaction” means, collectively, (i) the Transactions, (ii) the transactions contemplated by the Redemption Agreement, and (iii) the Acquirer Financing.
“Contributor’s Knowledge” means the actual knowledge of any of Lindsay Rosenwald, Sam Berry and Robyn Hunter, of the relevant subject matter, after reasonable due inquiry.
“Contributor Parties” means Contributor and Contributor’s Affiliates, and their respective subsidiaries (but excluding Acquirer and the Acquirer Parties) and the equity holders, directors, officers, employees, contractors, agents and representatives of Contributor and Contributor’s Affiliates.
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
“Fortress Biotech Special Committee” means the special committee of independent directors of Contributor established by the board of directors on April 7, 2022.
“Founders Agreement” means the Founders Agreement by and between Contributor and the Target effective as of March 9, 2017.
“Fundamental Representations” means the representations and warranties set forth in Sections 4(b) and 4(c).
“GAAP” means generally accepted accounting principles as in effect in the United States.
“Governmental Authority” means any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including any governmental authority, agency, committee, department, board, commission or instrumentality of the United States, any state of the United States or any political subdivision thereof, and any tribunal, court or arbitrator(s) of competent jurisdiction.
“Indebtedness” means, without duplication, (a) indebtedness for borrowed money; (b) obligations for the deferred purchase price of property or services; (c) long or short-term obligations evidenced by notes, bonds, debentures, other debt securities, or other similar
​

3
​

​

instruments; (d) obligations under any derivative, interest rate, currency swap, foreign exchange or other hedging agreement or arrangement;
(a)capital lease obligations in accordance with GAAP; (f) reimbursement and other obligations under any letter of credit, bank guarantees, banker’s acceptance or similar credit transactions (in each case to the extent drawn); (g) guarantees made by any Person on behalf of any third party in respect of obligations of the kind referred to in the foregoing clauses (a) through (f); and (h) any unpaid interest, prepayment penalties, premiums, costs and fees that would arise or become due as a result of the prepayment of any of the obligations referred to in the foregoing clauses (a) through (g); provided, that Indebtedness shall not include accounts payable to trade creditors.
“Intellectual Property” means any and all rights, anywhere in the world, arising out of or associated with any of the following: (a) patents, patent applications, patent disclosures, inventions (whether patentable or not), and designs, including, without limitation, continuations, continuations-in-part, divisionals, provisionals, non-provisionals, reexemaminations, restorations, extensions, renewals, and reissues for any of the foregoing, and all other indicia of invention ownership; (b) copyrights (registered and unregistered), copyright applications, copyrightable subject matter, and works of authorship;
(b)trademarks, service marks, trade dress, business names, trade names, and other indicia of source, whether registered, unregistered, or existing at common law, including all goodwill associated therewith;
(c)domain names, websites, and web pages, and all content and data thereon; (e) know-how, trade secrets, and confidential or proprietary information, including, without limitation, processes, techniques, improvements, ideas, discoveries, developments, data, results, methods, tests, and other proprietary technologies and information; (f) software; and (g) all other proprietary information and intellectual property, in any form or media, and all goodwill associated therewith.
“InvaGen Agreements” means the agreements listed on Exhibit C attached hereto.
“Law” means laws, regulations, statutes, codes, rules, orders, permits, policies, licenses, certifications, decrees, standards, guidance, or interpretations imposed by any Governmental Authority.
“Liabilities” means any and all claims, causes of action, payments, charges, judgments, awards, settlements, assessments, liabilities, losses, damages, liens, penalties, interest, fines or costs and expenses, including any reasonable fees of attorneys, experts, consultants, accountants and other professional representatives and legal or other expenses incurred in connection therewith, whether arising by Applicable Law, contract, tort, voluntary settlement or otherwise.
“Management Services Agreement” means the Management Services Agreement by and between Contributor and the Target effective as of March 9, 2017.
“Order” means any order, injunction, judgment, decree, ruling, writ, assessment, award, subpoena, verdict, settlement or finding from any Governmental Authority.
​

4
​

​

“Ordinary Course” means, with respect to an action taken by any Person, that (a) such action is in the ordinary course of business and consistent with the past practices of such Person or (b) such action is taken in response to a pandemic (including the SARS-CoV-2 virus and COVID-19 disease), provided that such action is commercially reasonable and materially consistent with the actions taken by other companies in such industries in response to such pandemic.
“Outside Date” means the later of each of the following: December 31, 2022; or such other date as the Parties may agree.
“Party” means Contributor or Acquirer and “Parties” means both of Contributor and Acquirer.
“Person” means individuals or entities, including any corporation, limited liability company, joint venture, trust, body corporate (wherever located), unincorporated association, partnership or other entity.
“Product” means any product that, as of the Effective Date, is under development by the Target, including, without limitation, BAER-101.
“Regulatory Approval” has the meaning set forth in Section 4(i)(i).
“Regulatory Laws” has the meaning set forth in Section 4(i)(ii).
“Representatives” means a Person’s directors, officers, partners, members, managers, employees, agents or advisors (including attorneys, accountants, consultants, bankers and financial advisors) and any representatives of those advisors.
“Retained Agreement” means that certain Amended and Restated Future Advance Promissory Note, issued by the Target (as successor-in-interest to FBIO Acquisition Corp. III) in favor of Contributor dated May 11, 2022.
“SEC” means the Securities and Exchange Commission.
“Securities Act” means the Securities Act of 1933, as amended.
“Stock Exchange” means the Nasdaq Global Market.
“Target IP” has the meaning set forth in Section 4(j)(i).
“Target Material Adverse Effect” means any event, occurrence, fact, condition or change that (a) has had, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, results of operations, financial condition or assets of the Target; provided, however, “Target Material Adverse Effect” shall not include, either alone or in combination, any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions or conditions generally affecting the capital, credit or financial markets; (ii) conditions generally affecting the industries or markets in which the Target operates; (iii) acts of war (whether or not declared), armed hostilities or terrorism,
​

5
​

​

or the escalation or worsening thereof; (iv) acts of God, including any earthquakes, hurricanes, tornadoes, floods, tsunami, pandemic (including COVID-19) or other natural disasters; (v) any action required or permitted by this Agreement, or any action taken (or not taken) with the written consent of or at the request of Acquirer; (vi) any changes in Applicable Laws or accounting rules or principles, including GAAP, or any interpretations thereof; or (vii) the announcement or execution of this Agreement, pendency or completion of the Transactions; provided, however, that any effect resulting from a matter described in any of the foregoing clauses (i) through (iv) or (vi) may be taken into account in determining whether a Target Material Adverse Effect has occurred or is reasonably likely to occur to the extent such effect has a disproportionate adverse effect on the Target, taken as a whole, relative to other entities operating in the industries in which the Target operates.
“Target Securities” has the meaning set forth in Section 4(h)(iii).
“Third Party” means any Person other than a Party (or its Affiliates).
“Transaction Documents” means this Agreement and the Assignment and Assumption Agreement.
“Voting Target Debt” has the meaning set forth in Section 4(h)(iii).
2.Contribution of Shares.
(a)At the Closing (as defined below), on the terms and subject to the conditions set forth in this Agreement, Contributor shall contribute, assign, transfer, convey and deliver to Acquirer, and Acquirer hereby agrees to accept and receive, the Shares free and clear of all liens, security interests, equitable interests, charges, claims, mortgages, right of first refusal, deeds of trust, pledges, warrants, options, purchase rights, leases or other encumbrances (“Encumbrances”).
(b)Unless this Agreement is earlier terminated pursuant to Section 9, the closing (the “Closing”) of the Transactions contemplated by this Agreement, including the contribution of all of the Shares, shall take place remotely via the exchange of documents and signatures, no later than three Business Days after the satisfaction or waiver of the conditions set forth in Section 7 (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions), or at such other place, time or date as Acquirer and Contributor mutually agree in writing (the date on which the Closing occurs, the “Closing Date”).
3.Assignment and Assumption of Obligations.
(a)Assumption of Obligations. At the Closing, pursuant to the Assignment and Assumption Agreement and on the terms and subject to the conditions set forth in this Agreement, Contributor shall transfer and assign to Acquirer, and Acquirer shall assume and be solely liable for, all obligations, duties, covenants and Liabilities, known or unknown, foreseeable or unforeseeable, arising from, based upon, related to or associated with the Shares, Contributor’s obligations under the Assumed Contracts or Contributor’s ownership in the Target, regardless of
​

6
​

​

whether such obligations or Liabilities arose prior to, on or after the Effective Date (collectively, the “Assumed Obligations”).
(b)Assignment of Contracts; Transfer of Books and Records. At the Closing, pursuant to the Assignment and Assumption Agreement and on the terms and subject to the conditions set forth in this Agreement, (i) Contributor shall irrevocably assign to Acquirer all of the Assumed Contracts, including all rights and obligations thereto, and (ii) Acquirer shall irrevocably accept all of Contributor’s rights and obligations in, to, and under the Assumed Contracts. In connection with the foregoing assignment, promptly following the Closing, Contributor shall transfer to Acquirer all books and records that it owns or controls to the extent exclusively related to the Shares, the Target, and/or the Assumed Contracts.
4.Representation and Warranties of Contributor. Contributor hereby represents and warrants to Acquirer at the Effective Date and at the Closing Date as follows:
(a)Organization and Good Standing. Contributor and, to Contributor’s Knowledge, the Target are corporations, validly existing and in good standing under the laws of the State of Delaware, and Contributor has the requisite power and authority to own the Shares.
(b)Authorization. Contributor has full power and authority to execute and deliver the Transaction Documents, to perform its obligations under the Transaction Documents, and to consummate the Transactions contemplated by this Agreement. The execution and delivery of the Transaction Documents by Contributor and the consummation by Contributor of the Transactions have been duly authorized by all necessary action on the part of Contributor. Each Transaction Document has been duly executed and delivered by Contributor and, assuming due execution and delivery by Acquirer, constitutes a legal, valid and binding obligation of Contributor, enforceable against Contributor in accordance with its terms, subject to the effects of bankruptcy, insolvency, reorganization, moratorium and other similar Applicable Laws affecting or relating to the rights of creditors generally, as well as to principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).
(c)Title to Shares. Contributor owns and holds the Shares beneficially and of record, free and clear of any Encumbrances and has full power and authority to transfer and dispose of all of the Shares, free and clear of any Encumbrances. Upon the payment for and the delivery of the Shares as provided in this Agreement, Acquirer will acquire good and valid title to the Shares, free and clear of any Encumbrances. Contributor does not own or hold any Target Securities, other than the Shares.
(d)Litigation. There is no Action or Order pending or, to Contributor’s Knowledge, threatened: (i) against or affecting Contributor that seeks to restrain or prohibit or otherwise challenge the consummation, legality or validity of the Transactions; (ii) subject to satisfaction of the conditions of Section 7 of this Agreement, against Contributor with respect to its ownership of the Shares; or (iii) to Contributor’s Knowledge, against or affecting the Target, its operations, or any Product.
​

7
​

​

(e)Consents and Approvals.
(i)The execution, delivery and performance by Contributor of this Agreement and the other Transaction Documents and the consummation by Contributor of the Transactions contemplated hereby and thereby will not (a) result in a violation of the organizational or constitutional documents of Contributor or the Target, (b) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any contract to which Contributor or the Target is a party, or (c) result in a violation of any Applicable Law by Contributor, the Target, or by which any property or asset of Contributor or the Target is bound or affected.
(ii)No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Authority, is required by or with respect to Contributor or the Target in connection with the execution and delivery of the Transaction Documents or the consummation of the Transactions contemplated thereunder; and no consent, approval or authorization from, or any waiver by, any Third Party pursuant to any contract to which Contributor or the Target is a party is required in connection with the execution and delivery of the Transaction Documents or the consummation of the Transactions contemplated thereunder.
(f)Scope of Transferred Assets. The Shares, together with the Assumed Contracts and all related books and records, represent all of the assets, whether tangible or intangible, owned or controlled by Contributor that relate to the Target, other than the Retained Agreement.
(g)Assumed Obligations; Target Liabilities and Indebtedness.
(i)Other than obligations arising in the Ordinary Course from and after the Closing under the Assumed Contracts, there are no material outstanding Assumed Obligations.
(ii)To Contributor’s Knowledge, Schedule 4(g)(ii) sets forth a complete and accurate list of each Target Liability existing and outstanding as of the Effective Date that, individually, is in excess of $25,000. To Contributor’s Knowledge, the Target’s Liabilities, as of the Effective Date, do not exceed, in aggregate, $100,000, excluding the Liabilities arising under the Baergic License Agreements.
(iii)To Contributor’s Knowledge, the Target has not incurred any Indebtedness, other than under the Retained Agreement. As of March 31, 2022, the total principal, together with accrued but unpaid interest, outstanding under the Retained Agreement is $4,429,706.
(h)Capitalization.
(i)The Target has an authorized share capital of 250,000 Class A Shares and 50,000,000 shares of common stock.
(ii)As of the Effective Date, (i) 250,000 Class A Shares are issued and outstanding, (ii) 14,297,173 shares of common stock are issued and outstanding, and (iii) no other
​

8
​

​

shares of capital stock of, or other equity interests in, the Target were issued, reserved for issuance or outstanding.  All of the outstanding shares of capital stock of the Target have been duly authorized and validly issued, are fully paid and nonassessable and were issued in compliance with all Applicable Law and the Target’s organizational documents.
(iii)Other than as set forth on Schedule 4(h)(ii), there are no options, warrants, rights, convertible or exchangeable securities, “phantom” stock rights, stock appreciation rights, restricted stock units, restricted stock, stock-based performance units, commitments, contracts, arrangements or undertakings of any kind to which the Target is a party or by which it is bound (i) obligating the Target to issue, deliver or sell or cause to be issued, delivered or sold, additional shares of capital stock of, or other equity interests in, or any security convertible or exercisable for or exchangeable into any capital stock of, or other equity interest in, the Target, or any Voting Target Debt (as defined below), (ii) obligating the Target to issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, contract, arrangement or undertaking or (iii) that give any Person the right to receive any economic benefit or right similar to or derived from the economic benefits and rights accruing to holders of capital stock of, or other equity interests in, the Target (together with the Class A Shares and the issued and outstanding shares of common stock of the Target, the “Target Securities”). Except as otherwise contemplated by this Agreement, there are no outstanding contractual obligations of the Target to repurchase, redeem or otherwise acquire any shares of capital stock of the Target. There are no proxies, voting trusts or other agreements or understandings to which the Target is a party or is bound with respect to the voting of or giving consent by the capital stock of, or other equity interests in, the Target. There are no preemptive or similar rights granted by the Target to any holders of any class or series of securities of the Target. There are no outstanding bonds, debentures, notes or other obligations of the Target, the holders of which have the right to vote (or which are convertible into or exchangeable or exercisable for securities having the right to vote) with the Target’s stockholders on any matter (“Voting Target Debt”).
(iv)The Target does not have, and has never had, any subsidiaries or equity interest in any Person.
(i)Regulatory Matters.
(i)To Contributor’s Knowledge, the Target has obtained all necessary and applicable approvals, clearances, authorizations, licenses, and registrations (collectively, “Regulatory Approvals”) required to operate the Target’s business, as operated immediately prior to the Effective Date and the Closing Date, including, without limitation, for its drug development activities.  To Contributor’s Knowledge, there is no proceeding pending or threatened that would result in the termination, revocation, suspension or the imposition of a restriction on any such Regulatory Approval or other approval, or the imposition of any fine, penalty or other sanction for the violation of any such Regulatory Approval or other approval.
(ii)To Contributor’s Knowledge, the Products are being, and have been during the past three (3) years, developed and manufactured in material compliance with all applicable requirements under any Applicable Law, including those regarding non-clinical testing, clinical research, establishment registration, drug listing, good manufacturing practices, record-keeping, adverse event reporting, and reporting of corrections and removals, as applicable
​

9
​

​

(collectively, “Regulatory Laws”), and the Target is and has been during the past three (3) years in compliance in all material respects with all Regulatory Laws to the extent applicable.
(iii)To Contributor’s Knowledge, during the past three (3) years, the Target has, in a timely manner, filed with the applicable Governmental Authorities all material filings, documents, declarations, listings, registrations, reports, statements, amendments, supplements or submissions, including but not limited to adverse event reports, as may be applicable, that are required to be filed by it under the applicable Regulatory Laws, any such filings were in material compliance with applicable Regulatory Laws when filed, and the Target has not received written notice of any material deficiencies that have been asserted by any applicable Governmental Authorities with respect to any such filings.  To Contributor’s Knowledge: (A) each such filing was true and correct in all material respects as of the date of submission, or was corrected in or supplemented by a subsequent filing, and (B) any material and legally necessary or required updates, changes, corrections, amendments, supplements or modifications to such filings have been submitted to the applicable Governmental Authorities.
(iv)To Contributor’s Knowledge, during the past three (3) years, the Target has not received any written notification of any pending or threatened action, lawsuit, claim, investigation, proceeding or order alleging potential or actual non-compliance with any Regulatory Laws.
(v)To Contributor’s Knowledge, during the past three (3) years, the Target has not received, and is not presently subject to, any action, notice, warning, administrative proceeding, review, or investigation by any Governmental Authority, that (A) alleged or asserted that the Target violated any applicable Regulatory Laws, or (B) commenced, or threatened to initiate, any action, suit, claim, investigation, proceeding or order to withdraw, discontinue, terminate or amend an Regulatory Approval or any other approval required for the development, testing, manufacturing, packaging, labelling, distribution, promotion, storage, sale, marketing, import, export, or provision of any of the Products.
(j)Intellectual Property.
(i)To Contributor’s Knowledge, the Target solely and exclusively owns, or has the sole and exclusive right to use (in each case subject to the retained rights provisions, and only in the licensed territories and licensed fields, set forth in the Baergic License Agreements), all Intellectual Property (A) currently used by the Target in connection with the development of the Products, and/or (B) that is currently anticipated by Target to be used to develop, manufacture, and/or commercialize the Products (collectively, the “Target IP”), free and clear of Encumbrances.
(ii)To Contributor’s Knowledge, no Person has infringed, misappropriated, or violated, or is currently infringing, misappropriating, or violating, the Target IP.
(iii)To Contributor’s Knowledge, the development of the Products does not, and shall not, infringe, misappropriate, or violate the Intellectual Property of a Third Party.  Neither Contributor nor, to Contributor’s Knowledge, the Target has received any written claim
​

10
​

​

from a Third Party alleging that the development, manufacture, or commercialization of any Product, anywhere in the world, infringes, misappropriates, or otherwise violates the Intellectual Property of a Third Party.
(k)Assumed Contracts.
(i)Each Assumed Contract is a valid and binding agreement of Contributor, and, to Contributor’s Knowledge, the Target, and is in full force and effect in all material respects.
(ii)Contributor is in, and has been in, compliance, in all material respects, with the Assumed Contracts.
(l)Compliance of the Target.
(i)To Contributor’s Knowledge, the Target is in, and has been in, compliance, in all material respects, with all Applicable Laws with respect to its business, properties or assets, and the Target has not received any written notice of any violation of Applicable Law.
(ii)To Contributor’s Knowledge, the Target is in, and has been in, compliance, in all material respects, with all contracts and agreements to which the Target and/or any of its assets is bound, and the Target has not received written notice of any breach of any such contract or agreement, and no counterparty to any such contract or agreement is in violation thereof.
(iii)The Target has not received written notice of any breach of any Baergic License Agreement, and, to Contributor’s Knowledge, there are no facts or circumstances that could reasonably give rise to any party to any Baergic License Agreement asserting a claim for material breach by the other party of such agreement.  To Contributor’s Knowledge, the Target is in, and has been in, compliance, in all material respects, with the Baergic License Agreements, and no counterparty to either Baergic License Agreement is in material breach of such agreement.
(m)No Other Representations.  Except as expressly set forth in this Section 4, neither Contributor nor any other person has made or is making any representation or warranty of any kind, express or implied, at law or in equity, written or oral, in respect of Contributor, the Target, the Shares, or otherwise, or with respect to any information provided to Acquirer.  All other representations or warranties are hereby disclaimed by Contributor.
5.Representations and Warranties of Acquirer.  Acquirer hereby represents and warrants to Contributor at the Effective Date and at the Closing Date as follows:
(a)Organization and Good Standing.  Acquirer is a corporation, validly existing and in good standing under the laws of the State of Delaware and has the requisite power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on its business as currently conducted.
​

11
​

​

(b)Authorization.  Acquirer has full power and authority to execute and deliver the Transaction Documents, to perform its obligations under the Transaction Documents, and to consummate the Transactions contemplated by this Agreement.  The execution and delivery of the Transaction Documents by Acquirer and the consummation by Acquirer of the Transactions have been duly authorized by all necessary action on the part of Acquirer.  Each Transaction Document has been duly executed and delivered by Acquirer and, assuming due execution and delivery by Contributor, constitutes a legal, valid and binding obligation of Acquirer, enforceable against Acquirer in accordance with its terms, subject to the effects of bankruptcy, insolvency, reorganization, moratorium and other similar Applicable Laws affecting or relating to the rights of creditors generally, as well as to principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).
(c)Stock Exchange Listing.  The Acquirer Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed for trading on the Stock Exchange.  There is no Action or Order pending or, to Acquirer’s Knowledge, threatened against Acquirer by the Stock Exchange, the SEC or the Financial Industry Regulatory Authority to prohibit, suspend or terminate the listing of the Acquirer Common Stock on the Stock Exchange.  Acquirer has taken no action with the intent to terminate the registration of the Acquirer Common Stock.
(d)Capitalization.
(i)Acquirer has an authorized share capital of 2,000,000 Acquirer Preferred Shares (of which 250,000 shares have been designated Acquirer Class A Preferred Shares, and the remainder are undesignated) and 50,000,000 Acquirer Common Shares.
(ii)As of the Effective Date, (i) 250,000 Acquirer Class A Preferred Shares and 16,793,693 Acquirer Common Shares are issued and outstanding, (ii) there were 1,014,256 Acquirer Common Shares underlying outstanding stock options and restricted share units, in each case issued under Acquirer’s 2015 Incentive Plan, (iii) there were 14,951 Acquirer Common Shares underlying outstanding warrants of Acquirer and (iv) no other shares of capital stock of, or other equity interests in, Acquirer were issued, reserved for issuance or outstanding.  All of the outstanding shares of capital stock of Acquirer have been duly authorized and validly issued, are fully paid and nonassessable and were issued in compliance with all Applicable Law and Acquirer’s organizational documents.
(iii)Except as disclosed in the Acquirer SEC Documents filed with or furnished to the SEC prior to the Effective Date, there are no options, warrants, rights, convertible or exchangeable securities, “phantom” stock rights, stock appreciation rights, restricted stock units, restricted stock, stock-based performance units, commitments, contracts, arrangements or undertakings of any kind to which Acquirer is a party or by which it is bound (i) obligating Acquirer to issue, deliver or sell or cause to be issued, delivered or sold, additional shares of capital stock of, or other equity interests in, or any security convertible or exercisable for or exchangeable into any capital stock of, or other equity interest in, Acquirer, or any Voting Acquirer Debt (as defined below), (ii) obligating Acquirer to issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, contract, arrangement or undertaking or (iii) that give any Person the right to receive any economic benefit or right similar to or derived from the economic benefits and rights accruing to holders of capital stock of, or other equity interests in,
​

12
​

​

Acquirer (together with the Acquirer Common Shares and the Acquirer Class A Preferred Shares, the “Acquirer Securities”).  Except as otherwise contemplated by this Agreement (including, for the avoidance of doubt, the InvaGen Redemption Agreement), there are no outstanding contractual obligations of Acquirer to repurchase, redeem or otherwise acquire any shares of capital stock of Acquirer.  There are no proxies, voting trusts or other agreements or understandings to which Acquirer is a party or is bound with respect to the voting of or giving consent by the capital stock of, or other equity interests in, Acquirer.  There are no preemptive or similar rights granted by Acquirer to any holders of any class or series of securities of Acquirer.  There are no outstanding bonds, debentures, notes or other obligations of Acquirer, the holders of which have the right to vote (or which are convertible into or exchangeable or exercisable for securities having the right to vote) with Acquirer’s stockholders on any matter (“Voting Acquirer Debt”).
(iv)Acquirer does not have, and has never had, any subsidiaries or equity interest in any Person.
(e)Brokers.  Acquirer has not retained any broker, finder or investment banking firm to act on its behalf which is entitled to any fee or commission from Acquirer upon consummation of the Transactions based upon arrangement made by or on behalf of Acquirer.
(f)SEC Filings.
(i)Acquirer has filed and furnished in a timely manner, in all material respects, all reports, schedules, forms, prospectuses and registration, proxy and other statements, in each case, required to be filed or furnished by it with or to the SEC (collectively, and in each case including all exhibits thereto and documents incorporated by reference therein, the “Acquirer SEC Documents”).  As of their respective effective dates (in the case of Acquirer SEC Documents that are registration statements filed pursuant to the requirements of the Securities Act) and as of the respective dates of the last amendment filed with the SEC (in the case of all other Acquirer SEC Documents), and the Acquirer SEC Documents complied in all material respects with the requirements of the Exchange Act and the Securities Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder, each as in effect on the applicable date referred to above, applicable to such Acquirer SEC Documents, and none of the Acquirer SEC Documents as of such respective dates contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
(ii)The Acquirer SEC Documents contain true and complete copies of the audited balance sheet as of December 31, 2021, and statements of operations, cash flows and stockholders’ equity (deficit) of Acquirer through December 31, 2021, together with the auditor’s report thereon, (the “Acquirer Financial Statements”).  Except as disclosed in the Acquirer SEC Documents, the Acquirer Financial Statements (i) fairly present in all material respects the financial position of Acquirer as at the respective dates thereof, and the results of operations and cash flows for the respective periods then ended, (ii) were prepared in conformity with GAAP applied on a consistent basis during the periods involved (except as may be indicated therein or in the notes thereto), and (iii) comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof.  The books and records of Acquirer have been, and
​

13
​

​

are being, maintained in all material respects in accordance with GAAP and any other applicable legal and accounting requirements.
(iii)Acquirer has established and maintains disclosure controls and procedures (as defined in Rule 13a-15 under the Exchange Act) and such disclosure controls and procedures are intended to ensure that material information relating to Acquirer is made known to Acquirer’s principal executive officer and its principal financial officer by others within Acquirer, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared.
(iv)There are no liabilities of Acquirer, whether fixed, contingent or otherwise, other than liabilities (i) disclosed and provided for in the balance sheet included in the Form 10­K filed by Acquirer for the year ending December 31, 2021, (ii) incurred in the Ordinary Course since December 31, 2021, (iii) incurred in connection with the Transactions or (iv) which are not material, individually, to Acquirer.  There are no “off balance sheet arrangements” as defined in Item 303 of Regulation S-K under the Securities Act involving Acquirer.
(v)During the past three (3) years, (i) Acquirer has not received any complaint, allegation, assertion or claim, regarding the accounting or auditing practices, procedures, methodologies or methods of Acquirer or its internal accounting controls, including any compliant, allegation, assertion or claim that Acquirer has engaged in questionable accounting or auditing practices, and (ii) no attorney representing Acquirer has reported evidence of a material violation of securities laws, breach of fiduciary duty or similar material violation by Acquirer or its officers, managers or employees to the board of directors of Acquirer or any committee thereof or to any director or officer of Acquirer pursuant to the rules of the SEC adopted under Section 307 of the Sarbanes-Oxley Act of 2002.
(g)Litigation.  There is no Action or Order pending or, to the Acquirer’s Knowledge, threatened: (i) against or affecting Acquirer that seeks to restrain or prohibit or otherwise challenge the consummation, legality or validity of the Transactions; or (ii) which would reasonably be expected to have, individually or in the aggregate, a material and adverse effect on Acquirer’s ability to consummate the Transactions.
(h)Compliance with Laws.  Acquirer is in compliance with all Applicable Laws with respect to its business, properties or assets, except, in each case, for any such noncompliance that would not have or reasonably be expected to have an Acquirer Material Adverse Effect.  Acquirer has not received any written notice of any violation of Applicable Law.
(i)Consents and Approvals.
(i)The execution, delivery and performance by Acquirer of this Agreement and the other Transaction Documents and the consummation by Acquirer of the Transactions contemplated hereby and thereby will not (a) result in a violation of the organizational or constitutional documents of Acquirer, (b) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any contract to which
​

14
​

​

Acquirer is a party, or (c) result in a violation of any Applicable Law by Acquirer or by which any property or asset of Acquirer is bound or affected.
(ii)No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Authority, is required by or with respect to Acquirer in connection with the execution and delivery of the Transaction Documents or the consummation of the Transactions contemplated thereunder; and no consent, approval or authorization from, or any waiver by, any Third Party pursuant to any contract to which Acquirer is a party is required in connection with the execution and delivery of the Transaction Documents or the consummation of the Transactions contemplated thereunder.
(j)Investment Representations.  Acquirer is acquiring the Shares for its own account, for investment purposes only and not with a view to the distribution (as such term is used in Section 2(a)(11) of the Securities Act) thereof.  Acquirer understands and acknowledges that the Shares have not been registered under the Securities Act or qualified under the blue sky or securities laws of any state and cannot be sold unless subsequently registered under the Securities Act or an exemption from such registration is available.
(k)No Material Adverse Effect.  Since December 31, 2021, there has been no event that has had, or could reasonably be expected to result in, an Acquirer Material Adverse Effect.
(l)Tax Advice.  Neither the Target, nor Contributor, nor any of their respective officers, directors, stockholders, agents, representatives or affiliates, has made statements, warranties or representations to Acquirer with respect to the income tax consequences of the transactions contemplated by this Agreement, except as set forth in Section 12(n) with respect to the Intended Tax Treatment.  Acquirer has reviewed with its own tax advisors the federal, state, local and foreign tax consequences of the transactions contemplated by this Agreement.  Acquirer relies solely on such advisors and not on any statements or representations of the Target, Contributor or any of their respective agents for the federal, state, local and foreign tax consequences to it that may result from the Transactions contemplated by this Agreement.
(m)Board Approval; Stockholder Vote.  The board of directors or other governing body of Acquirer (including any required committee or subgroup of the board of directors or other governing body of each such Person) has unanimously (i) approved and declared the advisability of this Agreement and the other Transaction Documents and the consummation of the Transactions, and (ii) determined that the consummation of the Transactions is in the best interests of Acquirer and its stockholders.
(n)Independent Investigation.  In entering into this Agreement, Acquirer has relied solely on the express warranties, representations, covenants, and agreements of Contributor in this Agreement, its independent investigation of, and judgment with respect to, the Shares and the assets and activities of the Target and the advice of its own Representatives (excluding Contributor and any Contributor Parties).  Acquirer is not relying upon any projections of any Contributor Party regarding prospective business activities of the Target.
​

15
​

​

6.Certain Covenants of the Parties.
(a)Interim Period.  During the period from the date hereof through the Closing Date (the “Interim Period”), Contributor, in its sole and reasonable discretion, shall manage its ownership of the Shares and provide services to, and, to the extent within Contributor’s control, operate the Target, in substantially the same manner in which it has done each of the foregoing prior to the Effective Date.  Without limiting the generality of the foregoing, during the Interim Period, except as expressly required by this Agreement, the Transactions contemplated hereby or by Applicable Law:
(i)Contributor shall not, without the prior written consent of Acquirer:
(1)sell, transfer, assign or encumber any of the Shares in any manner;
(2)vote for any proposal for winding up or liquidation of the Target or for any proceeding analogous to the same;
(3)vote to adopt any material change in the articles of incorporation or by-laws of the Target, or in or to the business, assets or liabilities of the Target; or
(4)amend, modify, or terminate any Assumed Contract; and
(ii)Contributor shall:
(1)Perform its obligations under and remain in compliance with all Assumed Contracts; and
(2)To the extent within its control, cause the Target to:
a.remain in compliance, in all material respects, with all Assumed Contracts and all other contracts and agreements to which the Target or any of its assets is bound (including, for the avoidance of doubt and without limitation, the Baergic License Agreements), and to refrain from modifying, amending, or terminating any such contracts and agreements;
b.preserve, maintain, and renew, as applicable, all Regulatory Approvals required to operate the Target’s business in substantially the same manner as operated immediately prior to the Effective Date;
c.use commercially reasonable efforts to prosecute, defend, and enforce the Target IP;
d.maintain and preserve, in all material respects, and not sell, transfer, assign, license, lease, encumber, or otherwise dispose of, the Target’s assets, other than in the Ordinary Course; and
​

16
​

​

e.comply with all Applicable Laws.
(b)Conduct of the Business of Acquirer.  Acquirer shall, during the Interim Period, except as expressly required by this Agreement or by Applicable Law or with the prior written consent of Contributor, (i) conduct its business in the Ordinary Course, and (ii) use its reasonable efforts to preserve intact its business organization.  Without limiting the generality of the foregoing, during the Interim Period, except as expressly required by this Agreement, the Transactions contemplated hereby, by Applicable Law, or in the Ordinary Course, Acquirer shall not, without the prior written consent of Contributor, which consent shall not be unreasonably withheld or delayed:
(i)amend or propose to amend its certificate of incorporation (including any certificate of designations) or by-laws;
(ii)make or declare any dividend or distribution to the Acquirer’s stockholders or make any other distributions in respect of any of Acquirer’s capital stock, (ii) split, combine, reclassify or otherwise amend any terms of any shares or series of Acquirer’s capital stock or (iii) purchase, repurchase, redeem or otherwise acquire any issued and outstanding share capital, outstanding shares of capital stock, restricted stock units, warrants or other equity interests of Acquirer, other than as contemplated by the Collective Transaction;
(iii)incur or assume any Indebtedness or guarantee any Indebtedness of another Person, issue or sell any debt securities or warrants or other rights to acquire any debt securities of Acquirer or guaranty any debt securities of another Person, other than as required, in Acquirer’s sole and reasonable discretion, to consummate the transactions contemplated by the Collective Transaction;
(iv)(A) issue any shares of Acquirer securities or securities exercisable for or convertible into capital stock, or (B) grant any additional options, warrants or restricted stock units with respect to Acquirer securities not outstanding on the date hereof, in each case, other than in the Ordinary Course or as contemplated by Acquirer’s 2015 Incentive Plan;
(v)make any loans, advances or capital contributions to, or investments in, any other Person;
(vi)grant any material Encumbrances on any property or assets (whether tangible or intangible) of Acquirer;
(vii)except as required by changes in GAAP, change any of its methods of accounting in any manner;
(viii)purchase or otherwise acquire (whether by merger or otherwise), or lease or license, any property or assets;
(ix)enter into any joint venture with a third party; or
(x)enter into any agreement, or otherwise become obligated, to take any action prohibited under this Section 6(b).
​

17
​

​

(c)Each Party shall, and shall cause their respective Affiliates to, do each of the following:
(i)Promptly inform the other Party of (and, at the other Party’s reasonable request, supply to such other Party) any communication (or other correspondence or memoranda) from or to, and any proposed understanding or agreement with, any Governmental Authority in connection with this Agreement or the Transactions.
(ii)Consult and cooperate with the other Party in connection with any analyses, appearances, presentations, memoranda, briefs, arguments and opinions made or submitted by or on behalf of any Party in connection with all meetings, actions, discussions and proceedings with Governmental Authorities relating to this Agreement or the Transactions, including, subject to Applicable Law, permitting the other Party to review in advance any proposed material written communication between it and any Governmental Authority.
(iii)Comply, as promptly as is reasonably practicable, with any requests received by a Party or any of its Affiliates under any Applicable Laws for information, documents or other materials relating to the Transactions.
(iv)If a Party or any of its Affiliates intends to participate in any meeting or discussion with any Governmental Authority with respect to the Transactions or any filings, investigations or inquiries made in connection with the Transactions, it shall, subject to Applicable Law, give the other Party reasonable prior notice of, and an opportunity to participate in, such meeting or discussion.
(d)Registration and Listing Matters.  Acquirer shall use reasonable efforts to cause the Acquirer Common Stock to continue to be registered as a class of securities under Sections 12(b) or 12(g) of the Exchange Act, shall comply, in all material respects, with its reporting and filing obligations under the Exchange Act, and shall not take any action or file any document (whether or not permitted by the Securities Act) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under the Exchange Act or Securities Act.  Acquirer shall use reasonable efforts to continue the listing and trading of Acquirer Common Stock on the Stock Exchange and, in accordance, therewith, shall use reasonable efforts to comply in all respects with Acquirer’s reporting, filing and other obligations under the bylaws or rules of the Stock Exchange, as applicable.
(e)InvaGen Redemption Agreement.  Acquirer shall use commercially reasonable efforts to enter into a share redemption agreement with InvaGen Pharmaceuticals Inc.  (“InvaGen”) the terms and form of which shall be mutually acceptable to Acquirer and the Fortress Biotech Special Committee (the “InvaGen Redemption Agreement”) pursuant to which (i) Acquirer will redeem 100% of the Acquirer Securities held or beneficially owned by InvaGen (the “INV Shares”), (ii) the InvaGen Agreements shall be terminated, in each case without any liability being imposed on the part of Contributor, and (iii) InvaGen’s negative control rights of Acquirer shall be terminated; provided, however, that the Fortress Biotech Special Committee shall indicate its approval of the InvaGen Redemption Agreement by written communication through its outside counsel, Cooley LLP, and Acquirer shall be entitled to rely upon such communication.
​

18
​

​

(f)Acquirer Financing.  Acquirer shall use commercially reasonable efforts to obtain financing through the sale of capital stock or debt securities of Acquirer (the “Acquirer Financing”) in amounts sufficient to (i) consummate the transactions contemplated by the InvaGen Redemption Agreement, and (ii) support the ongoing Product development efforts of the Target, the terms and form of which will be mutually acceptable to Acquirer and the Fortress Biotech Special Committee; provided, however, that the Fortress Biotech Special Committee shall indicate its approval of the terms and form of the Acquirer Financing by written communication through its outside counsel, Cooley LLP, and Acquirer shall be entitled to rely upon such communication.  In the event that Acquirer elects to execute the Acquirer Financing through a firm-commitment underwritten public offering of shares of Acquirer Common Stock and it is then subject to the limitations set forth under General Instruction I.B.6 of Form S-3 on the aggregate offering amount that may be offered and sold by it under its registration statement on Form S-3 (File No.  333-261520) declared effective on December 10, 2021, Acquirer shall prepare and file with the SEC within 30 days after the date hereof a Form S-1 or any similar long-form registration statement that may be available at such time (“Form S-1”) registering the shares of Acquirer Common Stock to be sold in the Acquirer Financing and shall use its reasonable efforts to cause such Form S-1 to be declared effective by the SEC under the Securities Act no later than 120 days after the date of filing of the Form S-1.
(g)Public Disclosure.  The Parties agree to consult with each other before issuing or making, and to provide each other reasonable prior opportunity to review, comment upon and concur with, and use all reasonable efforts to agree on, any press release, public statement or public disclosure with respect to the Transaction Documents or the Transactions contemplated hereby or thereby, and further agree not to issue any such press release, public statement or public disclosure without the prior written consent of the other Parties.
(h)Assistance and Cooperation.
(i)Prior to the Closing, upon the terms and subject to the conditions set forth in this Agreement, each Party agrees to use all reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, and to assist and cooperate with the other Party in doing, all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the Transactions contemplated by this Agreement, including taking all reasonable acts necessary to cause the conditions precedent set forth in Section 7 to be satisfied.
(ii)Prior to, and from and after, the Closing, each Party shall duly execute and deliver, or cause to be executed and delivered, such further instruments and do and cause to be done such acts and things, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.
(iii)From and after the Closing, in the event that either Party identifies (A) undocumented services provided by Contributor to the Target prior to the Closing, and/or (B) documentation, records, or other information held by Contributor that relates to the Target,
​

19
​

​

such Party will promptly notify the other, and the Parties will cooperate in good faith to enable the Target to operate in substantially the same manner as operated immediately prior to the Closing.
(iv)Reversion.  Notwithstanding anything to the contrary herein, if at any time during the twelve (12) month period following the Closing Date, the Stock Exchange terminates the listing of Acquirer’s Common Stock on the Stock Exchange, effective during such twelve (12) month period, then, to the fullest extent permissible under Applicable Law, upon written notice by Contributor describing such termination of listing, Acquirer shall no later than fifteen (15) days following such written notice transfer back and assign to Contributor all of the Shares and Assumed Contracts, on an “as is, where is” basis, and Acquirer shall execute any and all requested assignment documents evidencing such assignment and Acquirer will cooperate in good faith to enable such transfer and assignment.
(i)Retained Agreement; Management Services Agreement.  Acquirer agrees and acknowledges that during the Interim Period, (i) Contributor may, in its sole discretion, continue to provide additional funds to the Target under the Retained Agreement and (ii) the fees due to Contributor pursuant to the Management Services Agreement shall continue to accrue in accordance with its terms.
7.Conditions Precedent to Closing.
(a)Conditions Precedent to Obligations of the Parties.  The respective obligations of the Parties to consummate the Transactions are subject to the fulfillment, on or prior to the Closing Date, of each of the following conditions (which may be waived by the Parties, in whole or in part, subject to Applicable Law, but which may not be waived by any Party unilaterally):
(i)InvaGen Redemption Agreement.  The closing and consummation of the InvaGen Redemption Agreement upon such terms and in form as shall be mutually acceptable to Acquirer and the Fortress Biotech Special Committee (as communicated in accordance with Section 6(e)), including the redemption by Contributor of all of the INV Shares from InvaGen and the termination of each of the InvaGen Agreements, in each case at or immediately prior to the Closing shall have occurred.
(ii)Acquirer Financing.  The closing and consummation of the Acquirer Financing upon such terms and in form as shall be mutually acceptable to Acquirer and the Fortress Biotech Special Committee (as communicated in accordance with Section 6(f)) at or immediately prior to the Closing shall have occurred, and in the event that Acquirer has elected to execute the Acquirer Financing through a firm-commitment underwritten public offering of shares of Acquirer Common Stock and filed a Form S-1 in accordance with Section 6(f), the Form S-1 shall have been declared effective by the SEC under the Securities Act.
(iii)Transaction Documents.  Contributor and Acquirer shall have each executed and delivered the Assignment and Assumption Agreement.
(iv)No Injunction or Prohibition.  No Applicable Law or Order will restrain, enjoin or prohibit the consummation of the Transactions.
​

20
​

​

(v)Contributor Authorizations and Approvals.  Contributor shall have obtained all authorizations and approvals required to consummate the Transactions.
(b)Conditions Precedent to Obligations of Contributor.  The obligations of Contributor to consummate the Transactions are subject to the fulfillment, prior to or on the Closing Date, of each of the following conditions (any or all of which may be waived by Contributor, in its sole discretion, in whole or in part, subject to Applicable Law):
(i)Representations and Warranties.  Each of the representations and warranties of Acquirer contained in this Agreement shall be true and correct in all material respects at and as of the Closing Date, except with respect to any representation and warranty which is qualified by materiality or Acquirer Material Adverse Effect, which representations and warranties shall be true and correct in all respects.
(ii)Covenants.  Acquirer shall have performed or complied in all material respects with each of Acquirer’s agreements, obligations, conditions, and covenants that must be performed or complied with by Acquirer under this Agreement as of or prior to the Closing.
(iii)Stock Exchange Listing.  Acquirer’s Common Stock shall be listed and trading on the Stock Exchange.  There shall be no Action or Order pending or threatened against Acquirer by the Stock Exchange, the SEC or the Financial Industry Regulatory Authority to prohibit, suspend or terminate the listing of the Acquirer Common Stock on the Stock Exchange.
(iv)Acquirer Financing.  The Acquirer Financing shall be in an amount no less than $7,500,000.
(v)SEC Compliance.  Immediately prior to Closing, Acquirer shall be in compliance in all material respects with the reporting requirements applicable to it under the Exchange Act.
(vi)Notice to Baergic.  Contributor shall have received evidence of written notice provided by Acquirer to Baergic as of the Closing Date that Acquirer agrees to assume the obligations of Contributor under the Assumed Contracts.
(c)Conditions Precedent to Acquirer’s Obligations.  Acquirer’s obligation to purchase the Shares and comply with the terms and conditions set forth in this Agreement shall be subject to and conditioned upon the satisfaction or waiver on the Closing Date of the following conditions precedent set forth below:
(i)Representations and Warranties.  Each of the representations and warranties of Contributor contained in this Agreement shall be true and correct in all material respects at and as of the Closing, except with respect to any representation and warranty which is qualified by materiality or material adverse effect, which representations and warranties shall be true and correct in all respects.
​

21
​

​

(ii)Covenants.  Contributor shall have performed or complied in all respects with each of Contributor’s agreements, obligations, conditions, and covenants that must be performed or complied with by Contributor under this Agreement as of or prior to the Closing.
(iii)Stock Certificates and Stock Power.  Contributor shall have delivered to Acquirer stock certificates representing the Shares, accompanied by an executed stock power transferring the Shares to Acquirer substantially in the form attached hereto as Exhibit B.
(iv)Acquirer Financing.  The Acquirer Financing shall be in an amount no less than $7,500,000.
(v)Target Material Adverse Effect.  No Target Material Adverse Effect shall have occurred prior to the Closing.
8.Limitations; Disclosures, Waivers and Acknowledgements.
(a)LIMITATION OF REPRESENTATIONS AND WARRANTIES.
(i)EXCEPT FOR CONTRIBUTOR’S REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, CONTRIBUTOR IS NOT MAKING ANY OTHER REPRESENTATIONS OR WARRANTIES, WRITTEN OR ORAL, STATUTORY, EXPRESS OR IMPLIED, CONCERNING CONTRIBUTOR, THE SHARES, OR THE BUSINESS, ASSETS OR LIABILITIES OF CONTRIBUTOR, OR THE TARGET.  ACQUIRER ACKNOWLEDGES THAT, EXCEPT AS EXPRESSLY PROVIDED IN SECTION 4, CONTRIBUTOR HAS NOT MADE, AND CONTRIBUTOR HEREBY EXPRESSLY DISCLAIMS AND NEGATES, AND ACQUIRER EXPRESSLY WAIVES, ANY REPRESENTATION OR WARRANTY, EXPRESS, IMPLIED, AT COMMON LAW, BY STATUTE OR OTHERWISE RELATING TO, AND ACQUIRER HEREBY EXPRESSLY WAIVES AND RELINQUISHES ANY AND ALL RIGHTS, CLAIMS AND CAUSES OF ACTION AGAINST ANY CONTRIBUTOR PARTY OR ITS REPRESENTATIVES IN CONNECTION WITH, THE ACCURACY, COMPLETENESS OR MATERIALITY OF ANY INFORMATION, DATA OR OTHER MATERIALS (WRITTEN OR ORAL) FURNISHED TO ANY ACQUIRER PARTY AND ITS REPRESENTATIVES BY OR ON BEHALF OF ANY CONTRIBUTOR PARTY OR ANY OF THEIR REPRESENTATIVES IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS AGREEMENT SHALL ACT AS A RELEASE OF ANY ACT OF FRAUD BY A PARTY.
(ii)EXCEPT FOR ACQUIRER’S REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, ACQUIRER IS NOT MAKING ANY OTHER REPRESENTATIONS OR WARRANTIES, WRITTEN OR ORAL, STATUTORY, EXPRESS OR IMPLIED, CONCERNING ACQUIRER OR ITS BUSINESS, ASSETS OR LIABILITIES.  CONTRIBUTOR ACKNOWLEDGES THAT, EXCEPT AS EXPRESSLY PROVIDED IN SECTION 5, ACQUIRER HAS NOT MADE, AND ACQUIRER HEREBY EXPRESSLY DISCLAIMS AND NEGATES, AND CONTRIBUTOR EXPRESSLY WAIVES, ANY REPRESENTATION OR WARRANTY, EXPRESS, IMPLIED, AT COMMON LAW, BY STATUTE OR OTHERWISE RELATING TO, AND CONTRIBUTOR HEREBY
​

22
​

​

EXPRESSLY WAIVES AND RELINQUISHES ANY AND ALL RIGHTS, CLAIMS AND CAUSES OF ACTION AGAINST ANY ACQUIRER PARTY OR ITS REPRESENTATIVES IN CONNECTION WITH, THE ACCURACY, COMPLETENESS OR MATERIALITY OF ANY INFORMATION, DATA OR OTHER MATERIALS (WRITTEN OR ORAL) FURNISHED TO ANY CONTRIBUTOR PARTY AND ITS REPRESENTATIVES BY OR ON BEHALF OF ANY ACQUIRER PARTY OR ANY OF THEIR REPRESENTATIVES IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS AGREEMENT SHALL ACT AS A RELEASE OF ANY ACT OF FRAUD BY A PARTY.
(b)As Is, Where Is.  Except as expressly provided in Section 4, Acquirer acknowledges and agrees that the Shares will be acquired in its then “AS IS, WHERE IS” condition and with all faults, with an expressed acceptance and understanding of the disclaimers contained in this Agreement.
(c)No Reliance.  Each Party acknowledges the disclaimers in Section 8(a), and acknowledges and affirms that except for the other Party’s representations and warranties expressly set forth in this Agreement, it has not relied upon any representation, warranty, statement, opinion or information in entering into or carrying out the Transactions and each Party waives all rights and remedies which but for Section 8(a) would or might have been available to it in respect of such representation, warranty, collateral contract, statement, assurance, opinion or information.
9.Termination.
(a)Termination of this Agreement.  At any time prior to Closing, either Party may terminate this Agreement as follows, and upon termination the Transactions shall be abandoned:
(i)By any Party not responsible for the failure for Closing to occur, if the Closing has not occurred prior to or on the Outside Date.
(ii)By express agreement of the Parties.
(iii)By either Party, if the other Party has breached or failed to perform any of its representations, warranties, covenants or agreements contained in this Agreement, which breach or failure to perform: (i) would cause the Conditions in Section 7(a), 7(b) or 7(c) (as applicable) not to be satisfied; and (ii) cannot be cured or, if curable, is not cured prior to the earlier of the twentieth day following written notice of such breach or failure to perform is given to the Party in default or the Outside Date; provided, however, that the terminating Party is not then in material breach of this Agreement such that it has prevented, or will prevent, the satisfaction of any of the Conditions in Section 7(a), 7(b) or 7(c) (as applicable).
(b)Effect of Termination.  If this Agreement is terminated by a Party under Section 9(a), all further obligations and liabilities of the Parties under this Agreement will shall terminate and become void and the Parties shall then be released from their respective obligations under this Agreement, except that the obligations in this Section 9(b) and Section 12 shall survive the termination of this Agreement.
​

23
​

​

10.Restored Benefits.
The Parties acknowledge and agree that, as a result of the termination of the InvaGen Agreements, certain of Contributor’s rights and benefits under the Acquirer Founders Agreement and Acquirer’s Third Amended and Restated Certificate of Incorporation, as amended, shall be restored, in each case in accordance with the terms thereof, including, without limitation, an equity fee and change of control fee under Sections 1.2(d) and (e), respectively, of the Acquirer Founders Agreement.  The Parties acknowledge and agree that such equity fee arising under Section 1.2(d) of the Acquirer Founders Agreement shall become due and owing from Acquirer to Contributor as a result of the consummation of the Acquirer Financing.  Notwithstanding the foregoing, the Parties do not intend for such change of control fee arising under Section 1.2(e) of the Acquirer Founders Agreement to be triggered as a result of the consummation of the Collective Transaction, and, accordingly, Contributor hereby irrevocably waives any such change of control fee accruing as a result of the Collective Transaction (including as combined with other occurrences, including, without limitation, a previous resignation of a member of Acquirer’s Board of Directors).
11.Indemnification; Survival.
(a)Contributor Indemnity.  From and after the Closing Date, and subject to the Cap set forth in Section 11(c), Contributor will indemnify Acquirer and its officers, directors, equity holders, agents and other representatives (collectively, the “Acquirer Indemnitees”), and hold each of them harmless from and against, and reimburse each of them with respect to, all Liabilities arising out of or resulting from:
(i)any breach by Contributor of any representation or warranty set forth in Section 4;
(ii)any breach by Contributor of a covenant or agreement made by Contributor in this Agreement; and
(iii)any fraud or gross negligence by Contributor or any of its officers, directors, equity holders, agents, or other representatives in connection with the Transactions
(b)Acquirer Indemnity.  From and after the Closing Date, and subject to the Cap set forth in Section 11(c), Acquirer will indemnify Contributor and its officers, directors, equity holders, agents and other representatives (collectively, the “Contributor Indemnitees”), and hold each of them harmless from and against, and reimburse each of them with respect to, all Liabilities arising out of or resulting from:
(i)any breach by Acquirer of any representation or warranty set forth in Section 5;
(ii)any breach by Acquirer of a covenant or agreement made by Acquirer in this Agreement; and
(iii)any fraud or gross negligence by Acquirer or any of its officers, directors, equity holders, agents, or other representatives in connection with the Transaction.
​

24
​

​

(c)Limits on Indemnification.  In no event shall the Liability of Contributor or Acquirer for any indemnification claims under this Agreement, including under Section 11(a) or Section 11(b), exceed $50,000, respectively (the “Cap”), unless such indemnity claim is being made in respect of fraud and/or under Section 11(a)(i) with respect to a breach of a Fundamental Representation.
(d)Indemnification Procedures.
(i)Written Notice.  If any Contributor Indemnitee or Acquirer Indemnitee (in either case, an “Indemnitee”) wishes to make an indemnification claim under this Section 11, such Indemnitee shall deliver a written notice (an “Indemnification Claim Notice”) to the other party hereto (the “Indemnitor”) (i) stating that such Indemnitee has paid, incurred, suffered or sustained, or reasonably anticipates that it may pay, incur, suffer or sustain Liabilities and (ii) specifying such Liabilities in reasonable detail (to the extent available), and, if applicable, the nature of the misrepresentation, breach of warranty or covenant to which such item is related.  An Indemnitee may update an Indemnification Claim Notice from time to time to reflect any change in circumstances following the date thereof.
(ii)Denial of Obligation to Indemnify.  In the case the Indemnitor shall object to the indemnification of an Indemnitee in respect of any claim or claims specified in the Indemnification Claim Notice or to the Indemnitee’s estimate of the amount of an indemnifiable Liabilities specified therein, the Indemnitor shall, within thirty (30) days after receipt of the Indemnification Claim Notice, deliver to the Indemnitee a written notice to such effect (an “Indemnification Claim Objection Notice”).  The Indemnitor and the Indemnitee shall, within the thirty (30) day period beginning on the date of receipt by the Indemnitee of the Indemnification Claim Objection Notice, attempt in good faith to agree upon the rights of the respective parties with respect to each of such claims (and/or the estimated amount thereof) to which the Indemnitor shall have so objected.  If the Indemnitee and the Indemnitor succeed in reaching agreement with respect to such matters, the Indemnitee and the Indemnitor shall promptly prepare and sign a memorandum setting forth such agreement.  If the Indemnitee and the Indemnitor fail to reach an agreement with respect to such matters during the relevant thirty (30) day period, then either party may commence an Action for final determination of such matters.
(e)Survival.  All representations, warranties, covenants, and agreements of each Party set forth in this Agreement will terminate and expire on, and will cease to have any further force or effect upon the twelve (12) month anniversary of the Closing Date, and from and after such twelve (12) month anniversary of the Closing Date, none of the Parties will have any responsibility or liability for any breach of any of such representations, warranties, covenants, and/or obligations set forth herein; provided, however, that those covenants and agreements contained in this Agreement or in any other agreement delivered pursuant to this Agreement that by their terms are to be performed in whole or in part after the Closing (collectively, the “Surviving Covenants”) and the Fundamental Representations shall survive until the expiration of the applicable statute of limitations.  Notwithstanding any provision to the contrary, nothing in this Section 11(c) shall limit the ability of a Party to this Agreement, to bring an Action against any other Person for fraud or intentional misrepresentation or obtain any remedy or recourse arising from or related thereto.
​

25
​

​

12.General Provisions.
(a)Confidentiality.  The parties acknowledge that, in the course of evaluating the Transactions contemplated hereby, each party and its representatives have and will become aware of proprietary or confidential information and documents of or relating to the Target, Contributor, and Acquirer and their respective Affiliates (“Confidential Information”), and that disclosure of such Confidential Information, or communication of such Confidential Information to third parties, could be detrimental to the other party or the Target.  Each party (each, a “Receiving Party”) covenants that prior to Closing, all Confidential Information and documents concerning the other party (including the Target, in the case of Contributor) (each a “Disclosing Party”) reviewed by a Receiving Party or its representatives in connection with this Agreement or the Transactions contemplated hereby shall be maintained in confidence and shall not be disclosed or used by the Receiving Party or its representatives without the Disclosing Party’s prior written consent, unless such Confidential Information (i) were, are now or become publicly available (other than through disclosure by a Receiving Party or its representatives), (ii) are required to be disclosed pursuant to any Applicable Law, (iii) were disclosed to a Receiving Party by a third party not subject to any duty of confidentiality to the Disclosing Party, (iv) are required to be disclosed by the rules of a securities exchange on which either party may from time to time be listed or the SEC, or (v) are required to be disclosed for the purpose of consummating the Transactions.  In the event that a Receiving Party or any of its representatives is required, pursuant to Applicable Law or for purposes of consummating any of the Transactions contemplated herein, to disclose any such Confidential Information referred to in this Section 12(a), such Receiving Party shall, to the extent reasonably practicable, provide the Disclosing Party with prompt written notice before such disclosure, sufficient to enable the Disclosing Party either to seek a protective order, at its expense, or another appropriate remedy mitigating, preventing or prohibiting such disclosure or to waive compliance with the provisions of this Section 12(a), or both.  In the event that the Closing shall not occur, the Receiving Party shall, and shall cause its representatives, to keep confidential and not use any such Confidential Information unless such Confidential Information is required to be disclosed pursuant to Applicable Law; provided that in such event, such Receiving Party shall, to the extent reasonably practicable, provide the Disclosing Party with prompt written notice before such disclosure, sufficient to enable the Disclosing Party either to seek a protective order, at its expense, or another appropriate remedy mitigating, preventing or prohibiting such disclosure or to waive compliance with the provisions of this Section 12(a), or both.
(b)Assignment; Binding Effect.  Subject to the limitations set forth in this Agreement, this Agreement will be binding upon and inure to the benefit of the executors, administrators, heirs, legal representatives, and successors of the parties in this Agreement.
(c)Governing Law.  This Agreement, and all claims or causes of action (whether in contract, in tort or by statute) that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), shall be governed by, enforced in accordance with, and be subject to the remedies available under the internal laws of the State of Delaware (excluding choice of law principles that would require the application of the Laws of a jurisdiction other than the State of Delaware), including its statutes of limitations.
​

26
​

​

(d)Jurisdiction.  This Agreement, the rights and duties of the Parties hereto, and any disputes (whether in contract, tort or statute) arising out of, under or in connection with this Agreement will be governed by and construed and enforced in accordance with the Laws of the State of Delaware, without giving effect to its principles or rules of conflict of laws to the extent such principles or rules would require or permit the application of the Laws of another jurisdiction.  The Parties irrevocably and unconditionally submit to the exclusive jurisdiction of the United States District Court for the District of Delaware or, if such court does not have jurisdiction, the Delaware state courts located in Wilmington, Delaware, in any action arising out of or relating to this Agreement.  The Parties irrevocably agree that all such claims shall be heard and determined in such a Delaware federal or state court, and that such jurisdiction of such courts with respect thereto will be exclusive.  Each Party hereby waives, and agrees not to assert, as a defense in any action, suit or proceeding arising out of or relating to this Agreement that it is not subject to such jurisdiction, or that such action, suit or proceeding may not be brought or is not maintainable in such courts or that the venue thereof may not be appropriate or that this Agreement may not be enforced in or by such courts.  The Parties hereby consent to and grant any such court jurisdiction over the person of such Parties and over the subject matter of any such dispute and agree that mailing of process or other papers in connection with any such action, suit or proceeding in the manner provided in Section 12(e) or in such other manner as may be permitted by Law, will be valid and sufficient service thereof.
(e)Notices.  All notices and other communications under this Agreement will be in writing.  Unless and until the Parties hereto are notified in writing to the contrary, all notices, communications and documents, if not delivered by hand, will be mailed, addressed to the addresses set forth below.  Notices and communications will be mailed by first class mail, postage prepaid, overnight courier, or sent by e-mail return receipt requested; documents will be mailed by registered mail, return receipt requested, postage prepaid or by e-mail return receipt requested.  All mailings and deliveries related to this Agreement will be deemed received only when actually received.
If to Contributor, addressed to:
Fortress Biotech, Inc.
1111 Kane Concourse
Suite 301
Bay Harbor Island, FL 33154
Attn: Sam Berry
E-mail: sberry@fortressbiotech.com
with a copy to (which shall not constitute notice):
Cooley LLP
50 Boylston Street
Boston, MA 02116
Attn: Miguel Vega; Claudia Torres
E-mail: mvega@cooley.com; ctorres@cooley.com
If to Acquirer, addressed to:
​

27
​

​

Avenue Therapeutics, Inc.
1140 Avenue of the Americas Floor 9
New York, NY 10036
Attn: CEO
with a copy to (which shall not constitute notice):
DLA Piper LLP (US)
The Marbury Building
6225 Smith Avenue
Baltimore, Maryland 21209-3600
Attn: Howard Schwartz
E-mail: howard.schwartz@us.dlapiper.com
(f)Counterparts.  This Agreement may be executed in any number of counterparts, each of which will be an original, but all of which together will constitute one instrument.
(g)Headings.  The headings contained in this Agreement are included for purposes of convenience only, and do not affect the meaning or interpretation of this Agreement.
(h)Entire Agreement.  This Agreement sets forth the entire understanding of the parties hereto and supersedes any prior written or oral agreements and understandings with respect to the subject matter of this Agreement.
(i)Amendments.  Any provision of this Agreement may be amended, supplemented, or changed, only by written instrument making specific reference to this Agreement signed by the Parties.
(j)Waiver.  The observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) by the Party entitled to the benefit thereof, if in writing and signed by the Party entitled to the benefit thereof.
(k)Expenses.  Except as otherwise provided in this Agreement, each of the Parties hereto shall bear their respective expenses incurred or to be incurred in connection with the execution and delivery of this Agreement and the consummation of the Transactions contemplated hereby and thereby.
(l)Severability.  In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.
(m)Specific Performance.  Each of the Parties agrees that this Agreement is intended to be legally binding and specifically enforceable pursuant to its terms and that Contributor and Acquirer would be irreparably harmed if any of the provisions of this Agreement are not performed in accordance with their specific terms and that monetary damages would not
​

28
​

​

provide adequate remedy in such event.  Accordingly, in addition to any other remedy to which a non-breaching Party may be entitled at law, a non-breaching Party shall be entitled to injunctive relief to prevent breaches of this Agreement and to specifically enforce the terms and provisions hereof.  No Party shall be required to post a bond or other security before it can obtain specific performance.  Each Party waives any defenses in any action for specific performance, including the defense that money damages would be adequate.
(n)Intended Tax Treatment.  The Contribution is intended to be a contribution by Contributor of the Shares and the Assumed Contracts (as defined below) to the capital of Acquirer pursuant to Section 118 of the Internal Revenue Code of 1986, as amended (the “Code”), that is tax-free to both Contributor and Acquirer (the “Intended Tax Treatment”).  Acquiror shall not, and shall not cause or permit the Acquiror Parties to, and Contributor shall not, and shall not cause or permit the Contributor Parties to, take any tax position that is inconsistent with the Intended Tax Treatment, except as otherwise required by a determination within the meaning of Section 1313(a) of the Code.
[SIGNATURE PAGE FOLLOWS]
​

29
​

​

The Parties have executed this Stock Contribution Agreement as of the date first set forth above.
	​

	​

	​

	​
	CONTRIBUTOR:

	​
	​

	​
	Fortress Biotech, Inc.

	​
	​

	​
	By: 
	/s/ Lindsay A. Rosenwald

	​
	Name:
	Lindsay A. Rosenwald, M.D.

	​
	Title:
	President, CEO and Chairman

	​
	​

	​
	ACQUIRER:

	​
	​

	​
	Avenue Therapeutics, Inc.

	​
	​

	​
	By: 
	/s/ David Jin

	​
	Name:
	David Jin

	​
	Title:
	Interim CEO and CFO

​
​

[Signature Page to Stock Contribution Agreement]

​

EXHIBIT A
FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT, dated as of [                     ] [         ], 2022 (this “Agreement”) is entered into between Fortress Biotech, Inc., a Delaware corporation (“Assignor”), and Avenue Therapeutics, Inc., a Delaware corporation (“Assignee”).
RECITALS
Assignor as Contributor and Assignee as Acquirer are parties to that certain Stock Contribution Agreement dated effective May 11, 2022 (the “Stock Contribution Agreement”). Capitalized terms used, and not otherwise defined, in this Agreement shall have the meaning ascribed in the Stock Contribution Agreement.
	B.
	In connection with the consummation of the Transactions, Assignor desires to sell, assign, transfer, convey and deliver to Assignee all of its right, title and interest in, to and under the Shares and Assumed Contracts.

	C.
	Assignee desires to accept such assignment, and in consideration thereof assume all obligations, Liabilities and duties of Assignor that arise out of the Shares and Assumed Contracts prior to, on, and after, the Closing Date.

THE PARTIES HERETO, intending to be legally bound and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, agree as follows:
OBLIGATIONS
	1.
	Assignor hereby irrevocably and unconditionally contributes, assigns, transfers, conveys and delivers to Assignee all of its right, title and interest in, to and under the Shares and Assumed Contracts, free and clear of any and all Encumbrances, other than the restrictions (including, without limitation, the transfer restrictions) imposed pursuant to applicable securities laws, and transfers to Assignee all of its obligations, Liabilities and duties that arise out of the Shares and Assumed Contracts, as applicable, prior to, on, and after, the Closing Date.

	2.
	Assignee hereby accepts such assignment by Assignor of all of Assignor’s right, title and interest in, to and under the Shares and Assumed Contracts and hereby assumes and shall be solely liable for, subject to the terms of the Stock Contribution Agreement, all of the obligations, Liabilities and duties, known or unknown, foreseeable or unforeseeable, arising from or based upon the Shares and Assumed Contracts.

	3.
	This Agreement is deemed to constitute the deed, endorsement, assignment or other instrument of conveyance, transfer or assignment as shall be necessary in order to vest and effect the transfers, assignments and conveyances contemplated hereby.

	4.
	Assignor and Assignee agree, from time to time on and after the Closing Date, upon the reasonable request of the other and without further consideration, to do, execute, acknowledge and deliver any and all documents and instruments which may be necessary or desirable to

​

​

​

fully or more effectively vest and effectuate the transfers, assignments and conveyances contemplated hereby.
	5.
	This Agreement may not be amended or supplemented except by written agreement signed by each party hereto.

	6.
	This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Any counterpart may be executed by electronic signature and such electronic signature shall be deemed an original.

	7.
	The provisions of Section 12 of the Stock Contribution Agreement are incorporated in this Agreement by reference and made a part hereof.

	8.
	This Agreement is executed and delivered pursuant to the Stock Contribution Agreement. This Agreement shall not be deemed to supersede, defeat, limit, alter, impair, enhance, or enlarge any right, obligation, claim, or remedy created by the Stock Contribution Agreement or any related document, and in the event of any conflict between this Agreement and the Stock Contribution Agreement, the Stock Contribution Agreement will control.

​

​

​

The Parties have executed this Stock Contribution Agreement as of the date first set forth above.
	​

	​

	​

	​
	CONTRIBUTOR:

	​
	​

	​
	Fortress Biotech, Inc

	​
	​

	​
	By:
	​

	​
	Name:

	​
	Title:

	​
	​

	​
	ACQUIRER:

	​
	​

	​
	Avenue Therapeutics, Inc.

	​
	​

	​
	By:
	​

	​
	Name:

	​
	Title:

​
​

[Signature Page to Stock Contribution Agreement]

​

EXHIBIT B
STOCK POWER
(Stock Assignment Separate From Certificates)
​
FORTRESS BIOTECH, INC. hereby fully and irrevocably contributes, assigns and transfers unto AVENUE THERAPEUTICS, INC. 250,000 shares of Class A Preferred Stock and 8,617,653 shares of Common Stock of BAERGIC BIO, INC., a Delaware corporation (the “Company”), standing in its name on the books of such Company, as represented by the Certificates noted below, and hereby irrevocably constitutes and appoints the Company’s secretary as its attorney, to transfer such stock on the books of the Company with full power of substitution in the premises.
Dated:                 , 2022
	​
	FORTRESS BIOTECH, INC.

	​
	​

	​
	By:
	​

	​
	Name:

	​
	Title:

​
	Certificate No.
	Shares

	​
	​

	​
	​

​
​

​

​

EXHIBIT C
INVAGEN AGREEMENTS
	1.
	Stockholders Agreement, dated November 14, 2018, by and among Avenue, InvaGen and the other stockholders party thereto;

	2.
	Guaranty, dated November 14, 2018, by and between Fortress and InvaGen;

	3.
	Voting and Support Agreement, dated November 14, 2018, by and among Avenue, InvaGen and the other stockholders party thereto;

	4.
	Waiver and Termination Agreement, dated November 14, 2018, by and among Avenue, InvaGen and Fortress;

	5.
	Fortress Restrictive Covenant Agreement, dated November 14, 2018, by and between Fortress and InvaGen;

	6.
	Indemnification Agreement, by and between Fortress and InvaGen; and

	7.
	Lu Restrictive Covenant Agreement, dated November 14, 2018, by and between InvaGen and Lucy Lu, M.D.

​Exhibit
10.1

 

Employment
Agreement

 

This
Employment Agreement (the “Agreement”) is made and entered into as of August 1, 2022 by and between Alan R. Blackman
(the “Executive”) and Sharps Technology, Inc., a Nevada corporation (the “Company”).

 

WHEREAS,
the Company requires the Executive to relocate to the United States:

 

WHEREAS,
the Company has asked the Executive to focus on the following Objectives and Responsibilities:

 

(i)
financing the requirements of the Company

 

(ii)
increasing the enterprise value of the Company

 

(iii)
develop strategic alliances

 

(iv)
direct the efforts of public and investor relations

 

(v)
direct the marketing efforts of the Company

 

(vi)
continue in the role of Co-Chairman of the board, Chief Operating Officer, Chief Investment Officer and Corporate Secretary

 

(vii)
such other responsibilities as decided by the Company

 

WHEREAS,
the Company desires to employ the Executive on the terms and conditions set forth herein; and

 

WHEREAS,
the Company recognizes that relocation to the US means the Executive will not be able to see his family for extended periods of time,
and

 

WHEREAS,
the Executive agrees to be employed by the Company on such terms and conditions.

 

NOW,
THEREFORE, in consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows:

 

1.
Term.
The Executive’s initial term of employment hereunder shall begin on the date of this Agreement (the “Effective Date”)
and continue until twenty-four (24) months from the Effective Date (the “Initial Term”). Thereafter, the Agreement shall
be deemed to be automatically extended, upon the same terms and conditions, for successive periods, unless either party provides written
notice of its intention not to extend the term at least 30 days prior to the end of the Initial Term or twenty-four (24) month extension
thereof. The period during which the Executive is employed by the Company hereunder is hereinafter referred to as the “Employment
Term.”

 

2.
Position and Duties.

 

2.1
Position. During the Employment Term, the Executive
shall serve as the Chief Investment Officer, Corporate Secretary and Chief Operating Officer of the Company. In such position, the Executive
shall have such duties, authority, and responsibilities as are consistent with the Executive’s position.

 

    	 

     

    

 

2.2
Duties. During the Employment Term, the Executive shall devote
substantially all of the Executive’s business time and attention to the performance of the Executive’s duties hereunder and
will not engage in any other business, profession, or occupation for compensation or otherwise which would conflict or interfere with
the performance of such services either directly or indirectly without the prior written consent of the Board.

 

2.3
Voting Rights. The Company agrees that they will file an amendment to the Certificate of Designation governing the Company’s
Series A Preferred Stock so that it shall entitle the holder (the share is held by the Executive) to 29.5% (raised from the current level
of 25%) of the voting power of the Company’s stockholders with respect to the election of directors.

 

3.
Place of Performance. The principal
place of Executive’s employment shall be the Company’s principal executive office currently located in New York; provided
that, the Executive may be required to travel for Company business, which expenses for travel reimbursement shall include the
Executive’s spouse, Noelene Blackman. To the extent, necessary for Executive’s personal reasons, the Executive may
work remotely so long as doing so does not interfere with the Executive’s responsibilities and that the Executive recognizes that
he will be required to spend considerable time near the Company’s executive office.

 

4.
Compensation.

 

4.1
Base Salary. The Company shall pay the Executive
a monthly rate of base salary of $22,000 in accordance with the Company’s customary payroll practices and applicable wage payment
laws. The Executive’s base salary, as in effect from time to time, is hereinafter referred to as “Base Salary.”
The Base Salary shall not be less than 80% of the salary of the Company’s Chief Executive Officer and shall be adjusted accordingly.

 

4.2
Termination Without Cause, Change of Control or Death. In the event that any of the following events occur during the Employment
Term, the Executive or the Executive’s estate, as applicable, shall be entitled to receive a lump sum payment in an aggregate amount
equal to twenty four (24) months of the Base Salary:

 

(i)
The Executive’s death;

 

(ii)
The Executive’s Termination Without cause or

 

(iii)
A change of control in the Company, which shall mean any acquisition of ownership by any entity or person or any change in the ownership
of more than fifty percent (50%) of the Company’s common stock.

 

4.3
Performance Bonus.

 

(i)
The Executive shall be eligible to receive a performance bonus (the “Bonus”). However, the decision to provide such
annual Bonus and the amount and terms of the Bonus shall be in the sole and absolute discretion of the Compensation Committee of the
Board (the “Compensation Committee”) during the term of this Agreement, based on the criteria set forth in Schedule
A hereto.

 

    	2

     

    

 

4.4
Equity Awards. During the Employment Term, the
Executive shall be eligible to participate in the 2022 Equity Incentive Plan or any successor plan, subject to the terms of the 2022
Equity Incentive Plan or successor plan, as determined by the Board or the Compensation Committee, in its discretion.

 

4.5
Fringe Benefits and Perquisites. During the Employment
Term, the Executive shall be entitled to fringe benefits and perquisites consistent with those provided to similarly situated executives
of the Company.

 

4.6
Employee Benefits. During the Employment Term, the Executive
shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in effect from
time to time (collectively, “Employee Benefit Plans”), on a basis which is no less favorable than is provided to other
similarly situated executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee Benefit
Plans.

 

(i)
During the Employment Term, the Executive and the Executive’s spouse,
shall be entitled to health insurance benefits to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans.

 

(ii)
During the Employment Period, Executive shall be entitled have the use of a corporate apartment, and an allowance of $2,000 per month
to account for the difference in dining and related costs compared with normal expenses when living outside the US., as well as reimbursement
for an auto rental, as necessary.

 

(iii)
The Executive shall be entitled to receive compensation for airfare expenses to travel to and from Australia/New Zealand on one (1) occasion
during the twelve (12) month period from the date of this Agreement.

 

4.7
Bonus. The Company acknowledges that the Executive shall be entitled to a $250,000 bonus for work performed in any capacity, in
the first half of 2022 up to the date of this Agreement. Such bonus will be paid 50% within 30 days of this Agreement, with the balance
of 50% paid prior to the end of 2022. The amount owed shall be accrued on the Company’s books and records and shall be paid accordingly.

 

4.8
Vacation; Paid Time Off. During the Employment
Term, Executive shall be entitled to twenty (20) paid vacation days per calendar year (prorated for partial years) in accordance with
the Company’s vacation policies, as in effect from time to time. The Executive shall receive other paid time off in accordance
with the Company’s policies as such policies may exist from time to time and as required by applicable law.

 

4.9
Business Expenses. The Executive shall be entitled to reimbursement
for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses incurred by the Executive in connection with
the performance of the Executive’s duties hereunder in accordance with the Company’s expense reimbursement policies and procedures.
..

 

    	3

     

    

 

4.10
Out of Country Tax Deduction. The Executive shall be entitled to reimbursement for loss of Executive’s out-of-country tax
deduction equal to $29,000 for 2022 and 2023. Such payment to be made within 30 days of this Agreement.

 

4.11
Indemnification. The Company shall indemnify and hold the Executive
harmless to the fullest extent applicable to any other officer or director of the Company/to the maximum extent permitted under applicable
law and the Company’s bylaws for acts and omissions in the Executive’s capacity as an officer, director, or employee of the
Company.

 

4.12
Clawback Provisions. Any amounts payable under
this Agreement are subject to any policy (whether in existence as of the Effective Date or later adopted) established by the Company
providing for clawback or recovery of amounts that were paid to the Executive. The Company will make any determination for clawback or
recovery in its sole discretion and in accordance with any applicable law or regulation.

 

5.
Termination of Employment. The Employment
Term and the Executive’s employment hereunder may be terminated by either the Company or the Executive at any time and for any
reason or for no particular reason; provided that, unless otherwise provided herein, either party shall be required to give the other
party at least 30 days advance written notice of any termination of the Executive’s employment.

 

5.1
For Cause, or Without Good Reason.

 

(i)
The Executive’s employment hereunder may be terminated by the Company for Cause or by the Executive without Good Reason and the
Executive shall be entitled to receive:

 

(ii)
any accrued but unpaid Base Salary which shall be paid on the date of the Executive’s termination within one (1) week following
the date of the Executive’s termination on the pay date immediately following the date of the Executive’s termination in
accordance with the Company’s customary payroll procedures;

 

(iii)
any earned but unpaid Bonus with respect to any completed calendar year immediately preceding the date of the Executive’s termination,
which shall be paid on the otherwise applicable payment date except to the extent payment is otherwise deferred pursuant to any applicable
deferred compensation arrangement; provided that, if the Executive’s employment is terminated by the Company for Cause or the Executive
resigns without Good Reason, then any such earned but unpaid Bonus shall be forfeited;

 

(iv)
reimbursement for unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance
with the Company’s expense reimbursement policy; and

 

(v)
such employee benefits (including equity compensation), if any, to which the Executive may be entitled under the Company’s employee
benefit plans as of the date of the Executive’s termination; provided that, in no event shall the Executive be entitled to any
payments in the nature of severance or termination payments except as specifically provided herein.

 

    	4

     

    

 

Items
5.1(a)(i) through 5.1(a)(iv) are referred to herein collectively as the “Accrued Amounts.”

 

For
purposes of this Agreement, “Cause” shall mean:

 

(i)
the Executive’s willful failure to perform the Executive’s duties (other than any such failure resulting from incapacity
due to physical or mental illness);

 

(ii)
the Executive’s willful failure to comply with any valid and legal directive of the Company;

 

(iii)
the Executive’s willful engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, materially injurious
to the Company or its affiliates;

 

(iv)
the Executive’s embezzlement, misappropriation, or fraud, whether or not related to the Executive’s employment with the Company;

 

(v)
the Executive’s conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent)
or a crime that constitutes a misdemeanor involving moral turpitude;

 

(vi)
the Executive’s willful material violation of the Company’s written policies or codes of conduct, including written policies
related to discrimination, harassment, performance of illegal or unethical activities, and ethical misconduct;

 

(vii)
the Executive’s willful material breach of any material obligation under this Agreement or any other written agreement between
the Executive and the Company; or

 

(viii)
the Executive’s willful engagement in conduct that brings or is reasonably likely to bring the Company negative publicity or into
public disgrace, embarrassment, or disrepute.

 

For
purposes of this provision, none of the Executive’s acts or failures to act shall be considered “willful” unless the
Executive acts, or fails to act, in bad faith or without reasonable belief that the action or failure to act was in the best interests
of the Company. The Executive’s actions, or failures to act, based upon authority given pursuant to a resolution duly adopted by
the Board or upon the advice of counsel for the Company shall be conclusively presumed to be in good faith and in the best interests
of the Company.

 

Except
for a failure, breach, or refusal which, by its nature, cannot reasonably be expected to be cured, the Executive shall have 10 business
days from the delivery of written notice by the Company within which to cure any acts constituting Cause.

 

    	5

     

    

 

In
the event that the Executive provides notice to the Company of a disagreement with the termination of this Agreement, the Company shall
be obligated to continue all payments under this Agreement until a final determination by a court. Such payments to include legal fee is
pursuant to the Indemnification provided for in Section 4.11 of this Agreement.

 

For
purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following, in each case during the
Employment Term without the Executive’s prior written consent:

 

(ix)
a material reduction in the Executive’s Base Salary other than a general reduction in Base Salary that affects all similarly situated
executives in substantially the same proportions;

 

(x)
a material reduction in the Executive’s Bonus opportunity;

 

(xi)
any material breach by the Company of any material provision of this Agreement or any material provision of any other agreement between
the Executive and the Company;

 

(xii)
the Company’s failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in
the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such
assumption occurs by operation of law;

 

(xiii)
the Company’s failure to nominate the Executive for election to the Board and to use its best efforts to have him elected and re-elected,
as applicable;

 

(xiv)
a material, adverse change in the Executive’s title, authority, duties, or responsibilities (other than temporarily while the Executive
is physically or mentally incapacitated or as required by applicable law); or

 

(xv)
a material adverse change in the reporting structure applicable to the Executive.

 

To
terminate the Executive’s employment for Good Reason, the Executive must provide written notice to the Company of the existence
of the circumstances providing grounds for termination for Good Reason within 10 days of the initial existence of such grounds and the
Company must have at least 10 days from the date on which such notice is provided to cure such circumstances. If the Executive does not
terminate the Executive’s employment for Good Reason within 10 days after the first occurrence of the applicable grounds, then
the Executive will be deemed to have waived the Executive’s right to terminate for Good Reason with respect to such grounds.

 

    	6

     

    

 

5.2
Without Cause or for Good Reason. The Employment Term and the
Executive’s employment hereunder may be terminated by the Executive for Good Reason or by the Company without Cause. In the event
of such termination, the Executive shall be entitled to receive the Accrued Amounts and the Executive’s execution, within 45 days
following receipt, of a release of claims in favor of the Company, its affiliates and their respective officers and directors in a form
provided by the Company (the “Release”) (such 45-day period, the “Release Execution Period”), and
the Release becoming effective according to its terms, the Executive shall be entitled to receive the following:

 

(i)
a lump sum payment equal to two (2) times the sum of the Executive’s Base Salary for the year in which the date of the Executive’s
termination occurs, which shall be paid within 10 days following the date of the Executive’s termination;

 

(ii)
a payment equal to the product of a fraction, the numerator of which is the number of days the Executive was employed by the Company
during the year of termination and the denominator of which is the number of days in such year (the “Pro Rata Bonus”).
This amount shall be paid on the date that annual bonuses are paid to similarly situated executives;

 

5.3
Notice of Termination. Any termination of the
Executive’s employment hereunder by the Company or by the Executive during the Employment Term shall be communicated by written
notice of termination (“Notice of Termination”) to the other party. The Notice of Termination shall specify:

 

(i)
the termination provision of this Agreement relied upon;

 

(ii)
to the extent applicable, the facts and circumstances claimed to provide a basis for termination of the Executive’s employment
under the provision so indicated; and

 

(iii)
the applicable date of termination, which shall be no less than 30 days following the date on which the Notice of Termination is delivered.

 

5.4
Resignation of All Other Positions. Upon termination
of the Executive’s employment hereunder for any reason, the Executive agrees to resign/shall be deemed to have resigned from all
positions that the Executive holds as an officer.

 

6.
Governing Law, Jurisdiction, and Venue.
This Agreement, for all purposes, shall be construed in accordance with the laws of New York without regard to conflicts of law principles.
Any action or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located
in the state of New York. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of
inconvenient forum to the maintenance of any such action or proceeding in such venue.

 

7.
Entire Agreement.
Unless specifically provided herein, this Agreement, contains all of the understandings and representations between the Executive and
the Company pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations
and warranties, both written and oral, with respect to such subject matter.

 

    	7

     

    

 

8.
Modification and Waiver.
No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by
the Executive and by the Chief Executive Officer of the Company. No waiver by either of the parties of any breach by the other party
hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar
or dissimilar provision or condition at the same or any prior or subsequent time.

 

9.
Severability. Should any provisions
of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall
not affect any other provisions hereof, and if such provision or provisions are not modified as provided above, this Agreement shall
be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.

 

10.
Captions.
Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement
is to be construed by reference to the caption or heading of any section or paragraph.

 

11.
Counterparts.
This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all of which taken together shall
constitute one and the same instrument.

 

12.
Section 409A.

 

12.1
General Compliance. This Agreement is intended
to comply with Section 409A or an exemption thereunder and shall be construed and administered in accordance with such intent. Notwithstanding
any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies
with Section 409A or an applicable exemption. Any nonqualified deferred compensation payments under this Agreement that may be excluded
from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded
from Section 409A to the maximum extent possible. For purposes of Section 409A, each installment payment provided under this Agreement
shall be treated as a separate payment. Any payments to be made under this Agreement upon a termination of employment shall only be made
upon a “separation from service” under Section 409A. Notwithstanding the foregoing, the Company makes no representations
that the payments and benefits provided under this Agreement comply with Section 409A, and in no event shall the Company be liable for
all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Executive on account of non-compliance
with Section 409A.

 

12.2
Specified Employees. Notwithstanding any other
provision of this Agreement, if any payment or benefit provided to the Executive in connection with the Executive’s termination
of employment is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A and the
Executive is determined to be a “specified employee” as defined in Section 409A(a)(2)(b)(i), then such payment or benefit
shall not be paid until the first payroll date to occur following the six-month anniversary of the date of the Executive’s termination
(the “Specified Employee Payment Date”). The aggregate of any payments that would otherwise have been paid before
the Specified Employee Payment Date shall be paid to the Executive in a lump sum on the Specified Employee Payment Date and thereafter,
any remaining payments shall be paid without delay in accordance with their original schedule.

 

    	8

     

    

 

12.3
Reimbursements. To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be
provided in accordance with the following:

 

(i)
the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses
eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year;

 

(ii)
any reimbursement of an eligible expense shall be paid to the Executive on or before the last day of the calendar year following the
calendar year in which the expense was incurred; and

 

(iii)
any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.

 

13.
Successors and Assigns.
This Agreement is personal to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall
be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign
(whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets
of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns.

 

14.
Representations of the Executive.
The Executive represents and warrants to the Company that:

 

The
Executive’s acceptance of employment with the Company and the performance of the Executive’s duties hereunder will not conflict
with or result in a violation of, a breach of, or a default under any contract, agreement, or understanding to which the Executive is
a party or is otherwise bound.

 

The
Executive’s acceptance of employment with the Company and the performance of the Executive’s duties hereunder will not violate
any non-solicitation, non-competition, or other similar covenant or agreement of a prior employer or third-party.

 

15.
Withholding.
The Company shall have the right to withhold from any amount payable hereunder any Federal, state, and local taxes in order for the Company
to satisfy any withholding tax obligation it may have under any applicable law or regulation.

 

16.
Survival.
Upon the expiration or other termination of this Agreement, the respective rights and obligations of the parties hereto shall survive
such expiration or other termination to the extent necessary to carry out the intentions of the parties under this Agreement.

 

17.
Acknowledgement of Full Understanding.
THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE
EXECUTIVE ACKNOWLEDGES AND AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE’S
CHOICE BEFORE SIGNING THIS AGREEMENT.

 

[signature
page follows]

 

    	9

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

	 	SHARPS
    TECHNOLOGY, INC.
	 	 	 
	  
	By:
    	/s/
                                            Soren Christiansen

    

	 	Name:	Soren
                                            Christiansen

    

	 	Title:	Co-Chairman

 

	ALAN
    R. BLACKMAN	 
	 	 
	Signature:	/s/
    Alan R. Blackman	 
	Print
    Name:	Alan
    R. Blackman	 

 

    	10

     

    

 

SCHEDULE
A—CRITERIA to DETERMINE BONUS

 

The
Company completes a financing resulting in gross proceeds of at least $20.0 Million.

 

The
Company increases its market capitalization to at least 5 times its current level with a goal of 10 times based on its current value.

 

The
Company completes a strategic alliance with a major health company which results in significant benefits to the Company.

 

The
Company is acquired or is the acquirer in a significant transaction.

 

    	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]